Abstract
Uracil DNA misincorporation and misrepair of DNA have been recognized as important events accompanying thymidylate synthase (TS) inhibition. dUTPase catalyses the hydrolysis of dUTP to dUMP, thereby maintaining low intracellular dUTP. We have addressed the relationship between dUTPase expression and cellular sensitivity to TS inhibition in four human lung tumour cell lines. Sensitivity (5-day MTT assay) to the growth inhibitory effects of the non-polyglutamatable, specific quinazoline TS inhibitor ZD9331, varied up to 20-fold (IC503–70 nM). TS protein expression correlated with TS activity (r 2= 0.88, P= 0.05). Intracellular concentrations of drug following exposure to ZD9331 (1 μM, 24 h) varied by ~2-fold and dTTP pools decreased by > 80% in all cell lines. No clear associations across the cell lines between intracellular drug concentrations, TS activity/expression, or TTP depletion could be made. dUTPase activity varied 17-fold and correlated with dUTPase protein expression (r 2= 0.94, P= 0.03). There was a striking variation in the amount of dUTP formed following exposure to ZD9331 (between 1.3 and 57 pmole 10–6cells) and was in general inversely associated with dUTPase activity. A large expansion in the dUTP pool was associated with increased sensitivity to a 24-h exposure to ZD9331 in A549 cells that have low dUTPase activity/expression. dUTPase expression and activity were elevated (approximately 3-fold) in two variants of a human lymphoblastoid cell line with acquired resistance to TS inhibitors, further suggesting an important role for this enzyme in TS inhibited cells. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aherne GW and Brown SD (1999) The role of uracil misincorporation in thymineless death. In Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy, AL Jackman (ed). pp 409–421. Humana Press Inc: Totowa, NJ
Aherne GW, Hardcastle A, Raynaud F and Jackman AL 1996a) Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of Tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells. Biochem Pharmacol 51: 1293–1301
Aherne GW, Hardcastle A, Ward E, Brown S and Jackman AL 1996b) In vitro and in vivo pharmacology of the non-polyglutamated quinazoline antifolate thymidylate synthase (TS) inhibitor, ZD9331. Ann Oncol 308: 89
Aherne GW, Hardcastle A, Brown SD, Skelton L, Findlay MPN and Jackman AL (1997) The effect of thymidylate synthase (TS) inhibitors on TS protein expression in human tumour cell lines measured by ELISA. 11th International Symposium on Chemistry and Biology of Pteridines and Folates, 407–410
Beck WR, Wright GE, Nusbaum NJ, Chang JD and Isselbacher EM (1986) Enhancement of methotrexate cytotoxicity by uracil analogues that inhibit deoxyuridine triphosphate nucleotidohydrolase (dUTPase) activity. Adv Exp Med Biol 195b: 97–104
Brown SD, Hardcastle A and Aherne GW (1997) Deoxyuridine triphosphatase (dUTPase) expression and cellular response to TS inhibitors. In Chemistry and Biology of Pteridines and Folates. Pfleider W, Rokos H (eds) pp 271–274. Berlin: Blackwell Science
Calvert AH, Jones TR, Dady PJ, Grzelakowska-Sztabert Paine RM, Taylor GA and Harrap KR (1980) Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistance. Eur J Cancer 16: 713–722
Canman CE, Lawrence TS, Shewach DS, Tang HY and Maybaum J (1993) Resistance to fluorodeoxyuridine induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate. Cancer Res 53: 1–6
Canman CE, Radany EH, Parsels LA, Davis MA, Lawrence TS and Maybaum J (1994) Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumour cells by expression ofEscherichia colideoxyuridine triphosphatase. Cancer Res 54: 2296–2298
Caradonna SJ and Adamkiewicz DM (1984) Purification and properties of the deoxyuridine triphosphate nucleotidohydrolase enzyme derived from HeLa S3 cells: comparison to a distinct dUTP nucleotidohydrolase induced in herpes simplex virus-infected HeLa S3 cells. J Biol Chem 259: 5459–5464
Cohen SS (1971) On the nature of thymineless death. Ann NY Acad Sci 106: 292–301
Copur S, Aibak,, Drake JC, Allegra CJ and Chu E (1995) Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49: 1419–1426
Curtin NJ, Harris AL and Aherne GW (1991) Mechanisms of cell death following thymidylate synthase inhibition: 2 deoxyuridine 5 triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res 51: 2346–2352
Estlin EJ, Balmanno K, Calvert AH, Hall AG, Lunec J, Newell DR, Pearson AD and Taylor GA (1997) The relationship between intrinsic thymidylate synthase expression and sensitivity to thymitaq in human leukaemia and colorectal carcinoma cell lines. Br J Cancer 76: 1579–1585
Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW (1997) Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to therapy. Br J Cancer 75: 903–909
Fisher TC, Milner AE, Gregory CD, Jackman AL, Aherne GW, Hartley JA, Drive C and Hickman J (1993) Bcl-2 modulation of apoptosis induced by anticancer drugs-resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 53: 3321–3326
Freemantle SJ, Jackman AL, Kelland LR, Calvert AH and Lunec J (1995) Molecular characterization of two cell lines selected for resistance to the folate-based thymidylate synthase inhibition, ZD1694. Br J Cancer 71: 925–930
Houghton JA, Harwood FG and Houghton PS (1994) Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res 54: 4967–4973
Houghton JA, Harwood FG and Tillman DM (1997) Thymineless death in colon carcinoma cells is mediated via Fas signaling. Proc Natl Acad Sci USA 94: 8144–8149
Houghton JA, Ebanks R, Harwood FG and Tillman DM (1998) Inhibition of apoptosis after thymineless stress is conferred by oncogenic K-Rasin colon carcinoma cells. Clin Cancer Res 4: 2841–2848
Jackman AL and Judson IR (1996) The new generation of thymidylate synthase inhibitors in clinical study. Exp Opin Invest Drugs 5: 719–736
Jackman AL, Alison DL, Calvet AH and Harrap KR (1986) Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5-8-dideazafolic acid (CB3717): Development, characterization, and cross resistance studies. Cancer Res 46: 2810–2815
Jackman AL, Kelland LR, Kimbell R, Brown M, Gibson W, Aherne GW, Hardcastle A and Boyle FT (1995) Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914–924
Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MC, Wardleworth JM and Boyle FT (1997) Cellular pharmacology and in vivo activity of a new anticancer agent ZD9331: A water-soluble, nonpolyglutamatable, quinazoline inhibitor of thymidylate synthase. Clin Cancer Res 3: 911–921
Jackson RC, Jackman AL and Calvert AH (1983) Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N- ((2-amino-4-hydroxy-6-quinazolinyl)-methyl)prop-2-ynylamino)benzoy)-L-glutamic acid (CB3717), on human lymphoblastoid cells. Biochem Pharmacol 32: 3783–3790
Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allergra CJ (1994) The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647
Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 55: 1407–1412
Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckman E, Weichselbaum RR, Allegra CJ and Vokes EE (1997) Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89: 308–313
Ju J, Kane SE, Lenz HJ, Danenberg KD, Chu E and Danenberg PV (1998) Desensitization and sensitization of cells to fluoropyrimidines with different antisense directed against thymidylate synthase messenger RNA. Clin Cancer Res 4: 2229–2236
Kobayashi H, Takemura Y, Miyachi H, Skelton L and Jackman AL (1995) Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate inhibitors. Jpn J Cancer Res 86: 1014–1018
Ladner R and Caradonna S (1997) Lowering dUTPase levels through antisense induces sensitivity to fluorodeoxyuridine in HT29 cells. Proc Am Assoc Cancer Res 38: 614
Ladner RD, McNulty DE, Carr SA, Roberts GD and Caradonna SJ (1996) Characterization of distinct nuclear and mitochondrial forms of human deoxyuridine triphosphate nucleotidohydrolase. J Biol Chem 271: 7745–7751
Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Grohen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L (1995) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumour response and overall survival. J Clin Oncol 14: 176–182
Lindahl T (1979) DNA glycosylases, endonucleases for apurinic/apyrimidinic sites, and base excision repair. Prog Nucleic Acid Res Mol Biol 22: 135–142
O’Connor BM, Jackman AL, Crossley PH, Freemantle SE, Lunec J and Calvert AH (1992) Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl N10 propargyl-5, 8-dideazafolic acid: a novel folate based TS inhibitor. Cancer Res 52: 1137–1143
Parsels LA, Parsels JD, Wagner LM, Loney TL, Radany EH and Maybaum J (1998) Mechanism and pharmacological specificity of dUTPase-mediated protection from DNA damage and cytotoxicity in human tumor cells. Cancer Chemother Pharmacol 42: 357–362
Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Fusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Hyrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ and Johnston PG (1997) Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923–1931
Rhee MS, Wang Y, Nair MG and Galivan J (1993) Acquisition of resistance to antifolates caused by enhanced (-glutamyl hydrolase activity. Cancer Res 53: 2227–2230
Skelton LA, Ormerod MG, Titley JC and Jackman AL (1998) Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry 33: 56–66
Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L and Danenberg PV (1984) Thymidylate synthase inhibition in malignant tumours and normal liver of patients given intraveneous 5-fluorouracil. Cancer Res 44: 4144–4150
Strahler JR, Zhu X-X, Hora N, Wang YK, Andres PC, Roseman NA, Neel JV, Turka L and Hanash SM (1993) Maturation stage and proliferation-dependent expression of dUTPase in human T-cells. Proc Natl Acad Sci USA 90: 4991–4995
van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JAM, Noordhuis P, Jansen G and Peters GJ (1999) Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin Cancer Res 5: 643–654
Webber S, Bartlett C, Boritzki TJ, Hillard JA, Howland EF, Johnston AL, Kosa M, Margosiak SA, Morse CA and Shetty DV (1996) AG337 is a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 37: 309–317
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Webley, S., Hardcastle, A., Ladner, R. et al. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331. Br J Cancer 83, 792–799 (2000). https://doi.org/10.1054/bjoc.2000.1358
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1358
Keywords
This article is cited by
-
Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells
BMC Cancer (2022)
-
Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity
Cell Death & Disease (2019)
-
An evaluation of thymidine phosphorylase as a means of preventing thymidine rescue from the thymidylate synthase inhibitor raltitrexed
Cancer Chemotherapy and Pharmacology (2006)
-
5-Fluorouracil: mechanisms of action and clinical strategies
Nature Reviews Cancer (2003)